12don MSN
The 'zombie cell' effect: New study explains chemotherapy resistance in lung and ovarian cancers
Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to ...
Chemotherapy causes harsh side effects because it targets fast-growing cancer cells along with healthy cells like hair follicles, gut lining, and bone marrow. This leads to fatigue, nausea, hair loss, ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The number of patients requiring first-line chemotherapy is expected to increase by more than 50% from 2018 to 2040, and in order to deliver optimal treatment, a significant increase in the ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...
You might get just one chemotherapy drug or a combination of them. Using a combination can make your treatment more effective because each drug attacks cancer in a different way. It also lowers the ...
News-Medical.Net on MSN
Tiny organism offers insight into neurological side effects of chemotherapy
Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.
Chemotherapy is a common treatment for cancer, but determining its effectiveness can be complex. There are key signs, tests, and factors to help you understand if chemotherapy is working and how to ...
Chemotherapy for stomach cancer can help slow the disease’s growth and control symptoms. However, it may cause some side effects. People with stomach cancer have cells in their stomach that grow ...
Hair has always been more than appearance for Lisa Steinhauser. It is her craft, her artistry and her expression. When a routine mammogram in December 2021 changed everything, so did her relationship ...
Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results